Skip to main content

Table 2 Selected RCTs, sorted by experimental drug tested, start date and publication date

From: Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy

Generic name drug tested

RCT

Trial name

Sample size

Twin studya

Start datec

Publication date

% Male

Age

mean ± SD or median (IQR)

FEV1 % predicted

mean ± SD

Reference

Tiotropium

NCT02172287

 

410

NCT02173691

Feb-99

Jul-02

75

64.9 ± 7.9

Not available

[32]

NCT00274014

 

1010

 

Oct-00

Mar-06

88

64.8 ± 9.3

35.6 ± 12.6

[27]

NCT00274547

 

1829

 

Sep-01

Sep-05

99

67.9 ± 8.6

39.4 ± 13.5

[33]

NCT00277264

 

913

 

Jan-02

Nov-07

60

66.9 ± 8.9

39.4 ± 12.0

[34]

NCT00144339

UPLIFT

5993

 

Dec-02

Oct-08

75

64.5 ± 8.5

45.3 ± 13.6

[12]

NCT00387088

 

3991

NCT00168844/NCT00168831

Sep-06

Oct-10

78

64.8 ± 9.1

49.3 ± 13.2

[35]

NCT00563381

POET-COPD

7376

 

Jan-08

Mar-11

75

62.4 ± 9.0

48.3 ± 13.9

[36]

NCT01126437

 

17 135

 

May-10

Oct-13

72

65.0 ± 9.1

47.9 ± 12.7

[37]

NCT01455129b

 

839

 

Nov-11

Feb-14

Not available

[38]

Formoterol

NCT00134979

 

847

 

Oct-04

Nov-08

78

62.6 ± 8.9

51.2 ± 13.1

[39]

Aclidinium

NCT00363896

ACCLAIM/COPD I

843

NCT00358436

Aug-06

Apr-11

79

62.3 ± 8.3

53.6 ± 15.2

[40]

NCT01001494

ATTAIN

828

 

Oct-09

Oct-12

67

62.4 ± 8.0

52.5 ± 14.1

[41]

NCT01044459

 

605

 

Nov-09

Dec-13

58

63.6 ± 9.7

52.3 ± 13.2

[42]

Indacaterol

NCT00463567

 

1683

 

Apr-07

Jul-10

63

63.6 ± 9.1

55.6 ± 14.7

[43]

NCT00567996

 

1002

 

Nov-07

Jun-11

75

63.6 ± 8.8

53.3 ± 13.9

[44]

NCT00792805

 

563

 

Nov-08

Feb-14

94

65.4 ± 8.8

49.9 ± 12.1

[45]

NCT00845728

INVIGORATE

3444

 

Mar-09

Sep-13

77

64.0 (40–91)

40.5 ± 6.0

[46]

Olodaterol

NCT00782210

 

624

NCT00782509

Nov-08

Jun-14

73

64.9 ± 8.4

48.9 ± 15.4

[28]

NCT00793624

 

904

NCT00796653

Jan-09

Jul-14

78

63.8 ± 8.7

51.2 ± 14.7

[29]

Glycopyrronium

NCT00929110

GLOW2

1066

 

Jun-09

Nov-12

64

63.7 ± 8.8

56.0 ± 13.3

[47]

NCT01005901

GLOW1

822

 

Oct-09

Dec-11

82

63.9 ± 9.2

54.5 ± 12.9

[48]

NCT01566604

GLOW7

460

 

Mar-12

Jan-15

96

64.8 ± 8.1

51.0 ± 12.4

[49]

Indacaterol + Glycopyrronium

NCT01120691

SPARK

741

 

Apr-10

May-13

75

63.3 ± 8.0

37.2 ± 8.1

[25]

NCT01202188

SHINE

2144

 

Sep-10

Dec-13

75

64.0 ± 8.8

55.2 ± 13.1

[50]

NCT01315249

ILLUMINATE

259

 

Mar-11

Mar-13

71

63.3 ± 8.0

60.3 ± 10.6

[51]

NCT01709903

LANTERN

676

 

Nov-12

June-15

91

65.1 ± 7.9

51.8 ± 12.9

[52]

NCT01782326

LANTERN

  

Jul-13

Recruiting

   

[26]

Vilanterol + Umeclidinium

NCT01313650

 

1532

NCT01313637

Mar-11

Oct-13

71

63.0 ± 8.9

47.4 ± 13.1

[53]

NCT01316900

 

1141

NCT01316913

Mar-11

Jun-14

69

62.9 ± 9.0

47.7 ± 13.0

[54]

NCT01777334

 

905

 

Jan-13

Dec-14

68

62.3 ± 8.5

46.4 ± 12.9

[55]

Tiotropium + Olodaterol

NCT01431274

 

2624

NCT01431287

Sep-11

Apr-15

73

64.0 ± 8.3

45.0 ± 11.7

[30]

  1. aA twin study is a RCT registered at ClinicalTrial.gov with identical design, selection criteria and primary outcomes of efficacy. bThis trial was the only one to apply an upper age limit, 85 years. cStart date registered on ClinicalTrials.gov
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us